TRYPSIN INDUCED VON WILLEBRAND FACTOR RELEASE FROM HUMAN ENDOTHELIAL CELLS IS MEDIATED BY PAR-2 ACTIVATION

By Storck J.   Kusters B.   Vahland M.   Morys-Wortmann C.   Zimmermann E.R.  

Thrombosis Research, Vol. 84, Iss. 6, 1996-12 ,pp. : 463-473

Elsevier

Access to resources Recommend Favorite

Activation of protein–tyrosine kinase pathways in human platelets stimulated with the A1 domain of von Willebrand factor

By Satoh Kaneo   Asazuma Naoki   Yatomi Yutaka   Fujimura Yoshihiro   Miura Shuji   Titani Koiti   Ozaki Yukio  

Platelets, Vol. 11, Iss. 3, 2000-05 ,pp. : 171-176

Informa Healthcare

Access to resources Recommend Favorite

von Willebrand disease type 2B must be always considered in the differential diagnosis of genetic thrombocytopenias with giant platelets

By Loffredo Giuseppe   Baronciani Luciano   Noris Patrizia   Menna Francesco   Federici Augusto B.   Balduini Carlo L.  

Platelets, Vol. 17, Iss. 3, 2006-05 ,pp. : 149-152

Informa Healthcare

Access to resources Recommend Favorite

Platelets, glycoprotein Ib-IX, and von Willebrand factor are required for FeCl 3 -induced occlusive thrombus formation in the inferior vena cava of mice

By Joglekar M.V.  

Platelets, Vol. 24, Iss. 3, 2013-05 ,pp. : 205-212

Informa Healthcare

Access to resources Recommend Favorite

Atipamezole, an Imidazoline-Type 2 -Adrenoceptor Inhibitor, Binds to Human Platelets and Inhibits Their Adrenaline-Induced Aggregation more Effectively than Yohimbine

By Mustonen P.   Savola J.-M.   Lassila R.  

Thrombosis Research, Vol. 99, Iss. 3, 2000-06 ,pp. : 231-237

Elsevier

Access to resources Recommend Favorite